

Contents

Preface to the second edition — V

Chapter 1

An introduction to biopharmaceutical products — 1

- 1.1 Definitions and background — 1
 - 1.1.1 Biopharmaceuticals — 1
 - 1.1.2 Recombinant medicines explained — 3
 - 1.1.3 Proteins: key ingredients in most biopharmaceutical products — 3
 - 1.1.4 A final comment regarding terminology — 7
- 1.2 Biopharmaceuticals versus conventional small-molecule pharmaceuticals — 7
- 1.3 Biopharmaceutical product classes and examples — 10
 - 1.3.1 Protein therapeutics — 10
 - 1.3.2 Vaccines — 11
 - 1.3.3 Gene therapies — 15
 - 1.3.4 Cell therapies — 16
 - 1.3.5 Biopharmaceutical impact — 17
- 1.4 Biopharmaceutical drug product: dosage forms and containers — 18
- 1.5 Biopharmaceutical drug product: quality — 21
- 1.6 Summary — 23

Chapter 2

An overview of processes and facilities for biopharmaceutical production — 25

- 2.1 Biopharmaceutical manufacturing processes – an overview — 26
 - 2.1.1 The main process — 26
 - 2.1.2 Supporting activities — 34
 - 2.1.3 Equipment for the main process and support activities — 36
 - 2.1.4 Measures of product output — 40
- 2.2 Process design — 42
- 2.3 Manufacturing facilities — 50
- 2.4 Summary — 58
- 2.5 Review questions — 60

Chapter 3

Current good manufacturing practice (CGMP) for biopharmaceutical production — 64

- 3.1 CGMP – an overview — 64
- 3.2 CGMP regulatory framework — 65
- 3.3 Notable CGMP requirements for biopharmaceutical manufacture — 67

3.3.1	Personnel —	67
3.3.2	Personnel gowning —	68
3.3.3	Cleanroom behaviors —	71
3.3.4	Equipment —	71
3.3.5	Documentation system: procedures, records/reports, and specifications —	74
3.3.6	Testing: raw materials, in-process, drug substance, and drug product —	79
3.3.7	Qualification and validation —	80
3.3.8	Deviations and corrective and preventive actions (CAPA) —	84
3.3.9	Batch disposition —	87
3.3.10	Post-marketing surveillance —	88
3.4	Summary —	89
3.5	Review questions —	92

Chapter 4

Upstream operations — 95

4.1	Describing cell growth —	95
4.2	Upstream processing and production modes: batch versus fed batch versus continuous —	101
4.3	Bioreactor equipment design —	106
4.4	CGMP considerations for upstream processing —	111
4.5	Upstream process parameters and input material attributes —	116
4.6	Upstream performance parameters —	118
4.7	Upstream process development —	119
4.8	Scaling up fermentation and cell culture —	121
4.9	Summary —	126
4.10	Review questions —	128

Chapter 5

Harvest operations, part 1: cell lysis — 131

5.1	Structure of cells commonly used in biopharmaceutical production —	132
5.2	The need for cell lysis: intracellular versus extracellular products —	136
5.3	Cell lysis methods —	140
5.4	High-pressure homogenizers —	143
5.5	Homogenizer process and performance parameters —	146
5.6	Procedure for a high-pressure homogenization step —	150
5.7	Summary —	150
5.8	Review questions —	152

Chapter 6**Harvest operations, part 2: solid-liquid separation by centrifugation — 154**

- 6.1 Solid-liquid separations in biopharmaceutical processes — 155
- 6.2 Centrifugation principles — 156
- 6.3 Solid-liquid separation by gravity — 157
- 6.4 Production centrifuges — 161
 - 6.4.1 Disc-stack centrifugation: an introduction — 162
 - 6.4.2 Disc-stack centrifuges: equipment details — 164
 - 6.4.3 Other types of production centrifuges — 167
- 6.5 Disc-stack centrifuge CGMP operating procedure — 169
- 6.6 Disc-stack centrifuge process and performance parameters — 170
- 6.7 Sigma factor, centrifugation step design, and scale-up — 173
- 6.8 Summary — 176
- 6.9 Review questions — 177

Chapter 7**Harvest operations, part 3: solid-liquid separation by filtration — 180**

- 7.1 Filtration definition — 180
- 7.2 Filtration applications in biopharmaceutical processing — 181
- 7.3 Normal-flow versus tangential-flow filtration — 182
- 7.4 Solids retention by filters — 183
- 7.5 Depth filtration — 184
 - 7.5.1 Depth filters and filter modules — 185
 - 7.5.2 Depth filtration equipment and procedures for production — 188
 - 7.5.3 Depth filtration parameters, performance, and design — 190
- 7.6 Tangential-flow MF overview — 197
- 7.7 Unit operations for solid-liquid separation methods: a comparison — 200
- 7.8 Other operations for solid-liquid separation — 201
 - 7.8.1 Acoustic wave separation — 202
 - 7.8.2 Flocculation — 202
 - 7.8.3 Magnetic cake filtration — 203
- 7.9 Summary — 203
- 7.10 Review questions — 204

Chapter 8**Purification operations: chromatography — 208**

- 8.1 Soluble impurities — 209
- 8.2 Chromatographic principles — 211
- 8.3 Creating separation: stationary phases, mobile phases, and properties of the solutes to be separated — 213

8.3.1	Protein properties —	214
8.3.2	The most common stationary phase: resins used in packed beds —	215
8.3.3	Other stationary phase formats: membrane adsorbers and monoliths —	220
8.3.4	Mobile phase properties and their impact on separation —	221
8.4	Chromatography performance —	223
8.5	Operational modes —	231
8.6	Typical chromatography procedures for CGMP manufacturing —	232
8.7	Chromatography equipment for biopharmaceutical production —	235
8.8	Process and performance parameters for chromatography —	242
8.9	Chromatography process design —	243
8.10	Validation considerations for chromatography steps —	248
8.11	Summary —	251
8.12	Review questions —	252

Chapter 9

Formulation operations: ultrafiltration — 256

9.1	Basis of separation in UF and applications —	257
9.2	UF equipment and process configurations for production —	259
9.3	TFF membranes and modules —	263
9.4	Typical TFF procedures for CGMP manufacturing —	269
9.5	Process and performance parameters for tangential-flow UF and MF —	274
9.6	TFF development and scale-up —	282
9.7	Validation considerations —	287
9.8	Single-pass TFF —	289
9.9	Summary —	291
9.10	Review questions —	292

Chapter 10

Summary and trends in biopharmaceutical processing — 296

Glossary — 301

References — 315

Index — 331